Elmind Capital LP Makes New Investment in Tyra Biosciences, Inc. $TYRA

Posted by Brenda Bartman on Aug 26th, 2026

Elmind Capital LP acquired a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 20,000 shares of the company’s stock, valued at approximately $638,800,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Millennium Management LLC increased its stake in shares of Tyra Biosciences by 28.2% during the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock worth $3,759,000 after purchasing an additional 89,024 shares during the period. Goldman Sachs Group Inc. grew its holdings in Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after buying an additional 13,896 shares in the last quarter. Woodline Partners LP bought a new position in Tyra Biosciences during the 1st quarter worth $931,000. Jane Street Group LLC bought a new position in Tyra Biosciences during the 1st quarter worth $324,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Tyra Biosciences by 9.8% during the second quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock worth $5,428,000 after buying an additional 50,836 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Stock Performance

TYRA opened at $26.69 on Wednesday. Tyra Biosciences, Inc. has a 52-week low of $11.70 and a 52-week high of $40.65. The firm has a market cap of $1.59 billion, a P/E ratio of -11.12 and a beta of 0.77. The business’s fifty day moving average is $29.68 and its 200-day moving average is $32.27.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, research analysts predict that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TYRA shares. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Tyra Biosciences in a research report on Thursday, May 14th. Wolfe Research began coverage on shares of Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating for the company. JonesTrading began coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 price objective for the company. Jefferies Financial Group restated a “buy” rating and set a $42.00 target price on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.90.

Read Our Latest Analysis on TYRA

Tyra Biosciences Company Profile

(Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.